__timestamp | Corcept Therapeutics Incorporated | Perrigo Company plc |
---|---|---|
Wednesday, January 1, 2014 | 882000 | 2613100000 |
Thursday, January 1, 2015 | 1361000 | 2891500000 |
Friday, January 1, 2016 | 2058000 | 3228800000 |
Sunday, January 1, 2017 | 3554000 | 2966700000 |
Monday, January 1, 2018 | 5215000 | 2900200000 |
Tuesday, January 1, 2019 | 5504000 | 3064100000 |
Wednesday, January 1, 2020 | 5582000 | 3248100000 |
Friday, January 1, 2021 | 5281000 | 2722500000 |
Saturday, January 1, 2022 | 5385000 | 2996200000 |
Sunday, January 1, 2023 | 6481000 | 2975200000 |
Unleashing insights
In the ever-evolving pharmaceutical industry, understanding cost structures is crucial for investors and stakeholders. This analysis delves into the cost of revenue trends for Corcept Therapeutics Incorporated and Perrigo Company plc from 2014 to 2023. Over this period, Corcept Therapeutics has seen a significant increase in its cost of revenue, growing by approximately 635% from 2014 to 2023. In contrast, Perrigo Company has maintained a relatively stable cost structure, with fluctuations around the $3 billion mark.
This comparative analysis highlights the dynamic nature of cost management in the pharmaceutical sector, offering valuable insights for strategic decision-making.
Eli Lilly and Company vs Perrigo Company plc: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Johnson & Johnson vs Corcept Therapeutics Incorporated
Cost of Revenue Trends: AbbVie Inc. vs Perrigo Company plc
Analyzing Cost of Revenue: Teva Pharmaceutical Industries Limited and Corcept Therapeutics Incorporated
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and Corcept Therapeutics Incorporated
Insmed Incorporated vs Corcept Therapeutics Incorporated: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Grifols, S.A. and Perrigo Company plc
Cost of Revenue: Key Insights for Cytokinetics, Incorporated and Perrigo Company plc
Cost Insights: Breaking Down PTC Therapeutics, Inc. and Perrigo Company plc's Expenses
Analyzing Cost of Revenue: Perrigo Company plc and Supernus Pharmaceuticals, Inc.
Cost of Revenue Trends: Perrigo Company plc vs Travere Therapeutics, Inc.
Cost of Revenue Trends: Perrigo Company plc vs Celldex Therapeutics, Inc.